Search research articles
Contact Us
Filters
Showing results (411-420 of 431) with videos related to
Page
of 44
Sort By:
Future Oncology (London, England)
|
June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer
Lior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
NEJM Evidence
|
March 6, 2023
AI Estimation of Gestational Age from Blind Ultrasound Sweeps in Low-Resource Settings
Teeranan Pokaprakarn, Juan C Prieto, Joan T Price, et al.
JAMA
|
August 1, 2024
Diagnostic Accuracy of an Integrated AI Tool to Estimate Gestational Age From Blind Ultrasound Sweeps
Jeffrey S A Stringer, Teeranan Pokaprakarn, Juan C Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Communications Medicine
|
October 17, 2022
A mobile-optimized artificial intelligence system for gestational age and fetal malpresentation assessment
Ryan G Gomes, Bellington Vwalika, Chace Lee, et al.
Genome Announcements
|
July 15, 2017
Genome Sequences of Five <i>Streptomyces</i> Bacteriophages Forming Cluster BG
Richard Donegan-Quick, Zane A Gibbs, Patricia O Amaku, et al.
Page
of 44
Search research articles
Search
Showing results (411-420 of 431) with videos related to
Sort By:
Page
of 44
Future Oncology (London, England)
|
June 27, 2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer
Lior Z Braunstein, Melissa P Mitchell, Hanna Bandos, et al.
NEJM Evidence
|
March 6, 2023
AI Estimation of Gestational Age from Blind Ultrasound Sweeps in Low-Resource Settings
Teeranan Pokaprakarn, Juan C Prieto, Joan T Price, et al.
JAMA
|
August 1, 2024
Diagnostic Accuracy of an Integrated AI Tool to Estimate Gestational Age From Blind Ultrasound Sweeps
Jeffrey S A Stringer, Teeranan Pokaprakarn, Juan C Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
Nature Cancer
|
March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results
Rashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Communications Medicine
|
October 17, 2022
A mobile-optimized artificial intelligence system for gestational age and fetal malpresentation assessment
Ryan G Gomes, Bellington Vwalika, Chace Lee, et al.
Genome Announcements
|
July 15, 2017
Genome Sequences of Five <i>Streptomyces</i> Bacteriophages Forming Cluster BG
Richard Donegan-Quick, Zane A Gibbs, Patricia O Amaku, et al.
Page
of 44